Uppsala, Sweden

Katarina Ranlund

USPTO Granted Patents = 4 



Average Co-Inventor Count = 5.5

ph-index = 1

Forward Citations = 12(Granted Patents)


Company Filing History:


Years Active: 2011-2024

Loading Chart...
Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Katarina Ranlund

Introduction

Katarina Ranlund is a notable inventor based in Uppsala, Sweden. She has made significant contributions to the field of immunology, particularly through her innovative patents. With a total of four patents to her name, her work focuses on enhancing immune responses through the use of adjuvants.

Latest Patents

One of her latest patents is titled "Quil A fraction with low toxicity and use thereof." This patent describes how Fraction A of Quil A can be utilized alongside at least one other adjuvant to create an adjuvant composition. The components included in this composition work synergistically to enhance the immune response and exhibit immunomodulating activity on co-administered antigens or immunogens. The patent also discusses various adjuvants that can be used, including saponins, cell wall skeletons, block polymers, lipopeptides, and derivatives of Lipid A from different bacterial species.

Career Highlights

Katarina has worked with prominent companies in the biotechnology sector, including Isconova AB and Novavax AB. Her experience in these organizations has allowed her to develop and refine her innovative ideas, contributing to advancements in vaccine development and immunotherapy.

Collaborations

Throughout her career, Katarina has collaborated with esteemed colleagues such as Bror Morein and Jill Ekstrom. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and the advancement of scientific research.

Conclusion

Katarina Ranlund's contributions to immunology through her patents and collaborations highlight her role as an influential inventor in the field. Her work continues to pave the way for advancements in vaccine technology and immune response enhancement.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…